cAMP/PKA signaling in endocrine hypertension: genetic mechanisms and pathophysiological insights

The cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) signaling pathway plays a central role in adrenal function, steroidogenesis, and blood pressure regulation. Increasing evidence suggests that dysregulation of this pathway contributes to several forms of hypertension, both endocrine and non-endocrine. A growing number of germline and somatic alterations affecting components of the cAMP/PKA axis have been implicated as key drivers of hypertensive disorders. Among these, activating pathogenic variants (PV) in <i>GNAS</i>, which encodes the stimulatory G protein α-subunit (Gsα) responsible for cAMP production, have been linked to cortisol excess. Mosaic <i>GNAS</i> PV <i>cause McCune-Albright syndrome</i>, which may present with ACTH-independent Cushing syndrome, while somatic <i>GNAS</i> PV have been identified in cortisol-producing adrenal adenomas. Germline inactivating variants in <i>PRKAR1A</i> are associated with <i>Carney complex and primary pigmented nodular adrenocortical disease (PPNAD).</i> Furthermore, germline alterations in phosphodiesterases such as <i>PDE11A</i> and <i>PDE8B</i>, which impair cAMP degradation, have been associated with Cushing syndrome and micronodular adrenal hyperplasia. Somatic activating PV in <i>PRKACA</i>, the gene encoding the catalytic subunit of PKA, have also been described in cortisol-producing adenomas. In primary aldosteronism, recent studies-including data from our group-suggest that germline variants in <i>PDE2A</i> and <i>PDE3B</i> may contribute to bilateral adrenal hyperplasia and autonomous aldosterone production by modulating intracellular cAMP levels. Additionally, gain-of-function PV in <i>PDE3A</i> have been associated with a familial form of salt-independent hypertension characterized by enhanced PKA signaling and vascular remodeling. This expanding body of evidence underscores the critical role of the cAMP/PKA pathway in the pathophysiology of distinct hypertensive phenotypes and highlights novel molecular mechanisms and potential therapeutic targets that merit further investigation.

Authors

Institutions

Publication Details

Journal
Frontiers in Endocrinology
Published
2026-02-24
DOI
https://doi.org/10.3389/fendo.2026.1748702
Primary Topic
Genomics and Rare Diseases
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

cAMP/PKA signaling in endocrine hypertension: genetic mechanisms and pathophysiological insights

Madson Quriroz Almeida, Jose Antonio B. Lima Sobrinho
Frontiers in Endocrinology
Genomics and Rare Diseases
article

cAMP/PKA signaling in endocrine hypertension: genetic mechanisms and pathophysiological insights

Madson Quriroz Almeida, Jose Antonio B. Lima Sobrinho
article en

Abstract

The cyclic adenosine monophosphate (cAMP)-protein kinase A (PKA) signaling pathway plays a central role in adrenal function, steroidogenesis, and blood pressure regulation. Increasing evidence suggests that dysregulation of this pathway contributes to several forms of hypertension, both endocrine and non-endocrine. A growing number of germline and somatic alterations affecting components of the cAMP/PKA axis have been implicated as key drivers of hypertensive disorders. Among these, activating pathogenic variants (PV) in <i>GNAS</i>, which encodes the stimulatory G protein α-subunit (Gsα) responsible for cAMP production, have been linked to cortisol excess. Mosaic <i>GNAS</i> PV <i>cause McCune-Albright syndrome</i>, which may present with ACTH-independent Cushing syndrome, while somatic <i>GNAS</i> PV have been identified in cortisol-producing adrenal adenomas. Germline inactivating variants in <i>PRKAR1A</i> are associated with <i>Carney complex and primary pigmented nodular adrenocortical disease (PPNAD).</i> Furthermore, germline alterations in phosphodiesterases such as <i>PDE11A</i> and <i>PDE8B</i>, which impair cAMP degradation, have been associated with Cushing syndrome and micronodular adrenal hyperplasia. Somatic activating PV in <i>PRKACA</i>, the gene encoding the catalytic subunit of PKA, have also been described in cortisol-producing adenomas. In primary aldosteronism, recent studies-including data from our group-suggest that germline variants in <i>PDE2A</i> and <i>PDE3B</i> may contribute to bilateral adrenal hyperplasia and autonomous aldosterone production by modulating intracellular cAMP levels. Additionally, gain-of-function PV in <i>PDE3A</i> have been associated with a familial form of salt-independent hypertension characterized by enhanced PKA signaling and vascular remodeling. This expanding body of evidence underscores the critical role of the cAMP/PKA pathway in the pathophysiology of distinct hypertensive phenotypes and highlights novel molecular mechanisms and potential therapeutic targets that merit further investigation.

Frontiers in EndocrinologyVol. 17
Instituto do Câncer do Estado de São Paulo (BR), Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (BR)
Fundação de Amparo à Pesquisa do Estado de São Paulo
Good health and well-being
Openalex Percentile: Top 43%
Genomics and Rare Diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.